WallStreetZenWallStreetZen

NASDAQ: RXRX
Recursion Pharmaceuticals Inc Earnings & Revenue

OverviewForecastEarnings
DividendOwnership

RXRX past revenue growth

How has RXRX's revenue growth performed historically?
Company
11.88%
Industry
145.73%
Market
17.2%
RXRX's revenue has grown faster... subscribe to Premium to read more.
Revenue Growth vs Industry Performance
RXRX's revenue has grown faster... subscribe to Premium to read more.
Revenue Growth vs Market Performance
RXRX's revenue growth is accelerating... subscribe to Premium to read more.
Accelerating Revenue Growth Performance

RXRX earnings and revenue history

Current Revenue
$44.6M
Current Earnings
-$328.1M
Current Profit Margin
-736%

RXRX Return on Equity

Current Company
-72.9%
Current Industry
-63.5%
Current Market
188%
RXRX's Return on Equity (-72.9%)... subscribe to Premium to read more.
High Return on Equity Performance

Be the first to know when RXRX announces earnings.

RXRX Return on Assets

Current Company
-50.9%
Current Industry
2.9%
RXRX is generating lower Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

RXRX Return on Capital Employed

Current Company
-59.25%
Current Industry
19.5%
RXRX's ability to generate Return... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

RXRX vs Biotech Stocks

TickerRevenueEBITDAEarningsY/Y RevenueY/Y Earnings
RXRX$44.58M-$299.66M-$328.07M+109.39%N/A
GPCR$0.00-$88.46M-$89.62MN/AN/A
FUSN$2.07M-$85.08M-$94.90M+19.84%N/A
SANA$0.00-$245.43M-$283.26MN/AN/A
GLPG$260.57M$240.55M$230.11M-5.51%+5.12%
View Top Biotech Stocks

RXRX earnings dates

Next earnings date
Jun 3, 2024

Recursion Pharmaceuticals Earnings & Revenue FAQ

What were RXRX's earnings last quarter?

On Invalid Date, Recursion Pharmaceuticals (NASDAQ: RXRX) reported Q4 2023 earnings per share (EPS) of -$0.42, up 40% year over year. Total Recursion Pharmaceuticals earnings for the quarter were -$93.00 million. In the same quarter last year, Recursion Pharmaceuticals's earnings per share (EPS) was -$0.30.

If you're new to stock investing, here's how to buy Recursion Pharmaceuticals stock.

What was RXRX's earnings growth in the past year?

As of Q2 2024, Recursion Pharmaceuticals's earnings has grown year over year. Recursion Pharmaceuticals's earnings in the past year totalled -$328.07 million.

What is RXRX's earnings date?

Recursion Pharmaceuticals's earnings date is Invalid Date. Add RXRX to your watchlist to be reminded of RXRX's next earnings announcement.

What was RXRX's revenue last quarter?

On Invalid Date, Recursion Pharmaceuticals (NASDAQ: RXRX) reported Q4 2023 revenue of $10.89 million up 20.36% year over year. In the same quarter last year, Recursion Pharmaceuticals's revenue was $13.68 million.

What was RXRX's revenue growth in the past year?

As of Q2 2024, Recursion Pharmaceuticals's revenue has grown 11.88% year over year. This is 133.86 percentage points lower than the US Biotechnology industry revenue growth rate of 145.73%. Recursion Pharmaceuticals's revenue in the past year totalled $44.58 million.
©2024 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.